Imagine a high-tech scanner that uses laser beams to 'read' the unique light patterns in a drop of blood or fluid. Instead of using chemical dyes, it uses AI to recognize the specific fingerprint of a disease. It's like having a digital library of biological signatures to spot illness without damaging the sample.
Clinical trials for Alzheimer's disease are often slowed by the difficulty of accurately screening and selecting the right patients based on biological markers.
An AI-augmented photonics device that uses non-destructive laser beams to identify label-free patterns in liquid samples, alongside an optimized biosensor.
If you are a drug development firm dealing with slow and inaccurate patient recruitment for Alzheimer's trials — this project developed an AI-augmented photonics platform that identifies disease biomarkers to screen patients faster.
If you are a diagnostic laboratory dealing with the need for non-destructive, label-free biological sampling — this project developed a device using focused laser beams that generates digital signals of light patterns for disease signatures.
If you are a personalized medicine provider dealing with the lack of precise biological profiles for patients — this project developed a digital library of biomarkers to accelerate personalized treatment delivery.
Based on available project data, there is no specific pricing or cost per test mentioned; however, the project received an EU contribution of EUR 2,495,850 for development.
The project is moving toward industrial scale by adhering to ISO 13485 standards and planning deployments in three separate studies across Europe, USA, and Asia.
The company has increased its Freedom to Operate (FTO) by filing an additional patent, with a portfolio including patents, trademarks, AI models, and trade secrets.
The project is working toward ISO 13485 compliance, CE-mark certification, and a potential FDA Breakthrough designation.
The project period runs from 2023-08-01 to 2025-07-31, with current efforts focused on achieving regulatory compliance and deploying initial studies.
The project is led by a single Portuguese SME (ILOF - Intelligent Lab on Fiber), meaning 100% of the industry ratio is concentrated in one agile entity. This structure allows for rapid decision-making and direct control over the IP portfolio, though it lacks the diverse academic or large-scale industrial partnerships typically seen in larger consortia.
Contact ILOF - Intelligent Lab on Fiber in Portugal
Contact us to explore licensing opportunities for AI-photonics biomarker detection.
